Botanix Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Botanix Pharmaceuticals şirketinin toplam hissedar öz sermayesi A$108.7M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$112.5M ve A$3.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$79.31m
Eşitlik	AU$108.73m
Toplam yükümlülükler	AU$3.73m
Toplam varlıklar	AU$112.46m

Son finansal sağlık güncellemeleri

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Jan 12

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BOT 'nin kısa vadeli varlıkları ( A$82.9M ) kısa vadeli yükümlülüklerini ( A$3.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: BOT un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BOT borçsuzdur.

Borcun Azaltılması: BOT son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BOT şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: BOT tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Botanix Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Recent updates

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

New minor risk - Share price stability

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

MD, President & Executive Chairman exercised options to buy AU$370k worth of stock.

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin